New York, NY – April 2, 2025 – Occam Global, a leading international executive search and leadership advisory firm, announced key executive placements and hiring trends for Q1 2025, reflecting the evolving priorities of the life sciences industry.
"We are seeing a notable uptick in hiring for Chief Business Officers (CBOs), driven by the challenging biotech funding environment of the past two years," said William Holodnak, Founder & CEO of Occam Global. "Companies are prioritizing strategic leadership that can navigate capital constraints and drive sustainable growth."
As a trusted partner in executive recruiting, board development, and leadership advisory, Occam Global continues to deliver elite talent across biotech, technology, and venture capital. The firm is known for its deep industry expertise, commitment to ethical leadership, and ability to connect visionary leaders with high-impact opportunities.
Key Executive Placements in Q1 2025
- Vidya Vasu Devan – Chief Investment Officer, GHIC
- Hannah Seitz – Chief Business Officer, LabGenius
- Laurens Kruidenier – Chief Scientific Officer, Nilo Therapeutics
- Luke Walker – Chief Medical Officer, Umoja Biopharma
- Emilio Emini & Lauren Silvernail – Board Members, Dynavax
- Mark Pykett – CEO, Orogon Therapeutics
- Purnanand Sarma – CEO, Aro Biotherapeutics
- Sudhir Rao – Chief Business Officer, Envisagenics
- Michael Bell – Chief Technology Officer, Chemify
- Wanmei Ou – Vice President, Data Science & Analytics, GSK
- Preetam Shah - Chief Strategy and Financial Officer, Elicio Therapeutics
- Namandjé Bumpus & Elaine Sun, Board Members, Recursion
With deep expertise in C-suite and board-level searches, Occam Global continues to place CEOs, CFOs, CBOs, COOs, CMOs, CTOs, CPOs, CCOs, General Counsel, and Heads of Regulatory Affairs in emerging and established life sciences companies worldwide.
For more insights, explore our latest blog:
🔹 Delightful Ambiguity: Defining Traits of the Ideal Biotech Chief Business Officer
About Occam Global
Occam Global is a trusted executive search, consulting, and investment partner for leaders and investors shaping the future of life sciences, deep tech, and venture capital. Since 2012, we’ve helped build high-performing teams and advised visionary companies from stealth to public markets. Our success stems from exceptional access to rare talent, deep sector expertise, and a commitment to results guided by elevated ethics and enlightened aggression.
